वृक्क धमनी एथेरोस्क्लेरोसिस (एथेरोस्क्लेरोटिक रेनोवैस्कुलर रोग, ARVD) प्रणालीगत एथेरोस्क्लेरोसिस की एक संवहनी अभिव्यक्ति है जो वृक्क धमनियों को प्रभावित करती है। प्रथम-पंक्ति प्रबंधन में हृदय-संवहनी जोखिम में कमी के साथ-साथ रक्तचाप नियंत्रण को लक्षित किया जाता है, जो विभिन्न प्रमुख चिकित्सा संस्थाओं के दिशानिर्देश-अनुशंसित सीमाओं का पालन करता है।
Intensive management of arterial hypertension is the single most important and modifiable cardiovascular risk factor, with the latest American Heart Association/American College of Cardiology and European Society of Cardiology guidelines recommending a target blood pressure <130/80 mm Hg and KDIGO recommending systolic blood pressure <120 mm Hg.
Initial antihypertensive therapy often includes multiple drugs, but RAAS blockers are preferred.
Hence, RAAS blockade is recommended in the setting of ARVD.
Lipid-lowering drugs are strongly recommended to achieve cholesterol targets appropriate to the level of cardiovascular risk; by definition, ARVD represents a clinical manifestation of atherosclerotic disease and should be considered to pose very high risk.
Antiplatelet therapy with at least a low dose of aspirin is also considered as standard care for secondary prevention of cardiovascular events.
Additional measures to manage ARVD risk include tobacco cessation and glycemic control.
View source ↗